Who are ABT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): abatacept (ABA), IV Abatacept, abatacept infusion, Abatacept subcutaneous, Abatacept (W12-W48), Belatacept LI (less intensive).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ABT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABT (ABT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4 modulator. Area: Immunology.

marketed CTLA-4 modulator CD80/CD86 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ABT (ABT) — Shanghai Public Health Clinical Center. Abatacept works by inhibiting T-cell activation through the CD80/CD86-CD28 costimulatory pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABT TARGET	ABT	Shanghai Public Health Clinical Center	marketed	CTLA-4 modulator	CD80/CD86
abatacept (ABA)	abatacept (ABA)	Bristol-Myers Squibb	marketed	CTLA-4 immunoglobulin fusion protein	CD80/CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
Abatacept subcutaneous	Abatacept subcutaneous	Bristol-Myers Squibb	phase 3	T-cell co-stimulation modulator	CD80/CD86
Abatacept (W12-W48)	Abatacept (W12-W48)	University Hospital, Montpellier	phase 3	T-cell costimulation inhibitor	CD80/CD86
Belatacept LI (less intensive)	Belatacept LI (less intensive)	Bristol-Myers Squibb	phase 3	T-cell costimulation blocker	CD80/CD86 (via CTLA4-Ig fusion protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4 modulator class)

Shanghai Public Health Clinical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT — Competitive Intelligence Brief. https://druglandscape.com/ci/abt. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing